Clinical Trial Update: Proof Of Concept : Immunogenicity and Safety of hepB Injection in the Dermis Using VAX-ID [Phase 1]

View source ↗

Summary

A Phase 1 proof-of-concept study evaluating the immunogenicity and safety of a Hepatitis B vaccine delivered in the dermis using VAX-ID, sponsored by Novosanis …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• VAX-ID Hepatitis B vaccine (hepatitis B vaccine delivered dermally via VAX-ID)

Snippet

Sponsor: Novosanis NV | Conditions: Hepatitis B | Phase 1 | Status: COMPLETED